KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBITDA (2016 - 2025)

Novavax (NVAX) has 16 years of EBITDA data on record, last reported at $14.2 million in Q4 2025.

  • For Q4 2025, EBITDA rose 110.86% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $452.8 million, up 281.9%, while the annual FY2025 figure was $452.8 million, 281.9% up from the prior year.
  • EBITDA reached $14.2 million in Q4 2025 per NVAX's latest filing, up from -$178.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $515.5 million in Q1 2025 and bottomed at -$825.0 million in Q4 2021.
  • Average EBITDA over 5 years is -$134.7 million, with a median of -$139.4 million recorded in 2024.
  • Peak YoY movement for EBITDA: plummeted 1931.06% in 2021, then soared 455.94% in 2025.
  • A 5-year view of EBITDA shows it stood at -$825.0 million in 2021, then skyrocketed by 70.44% to -$243.9 million in 2022, then grew by 24.73% to -$183.6 million in 2023, then increased by 28.59% to -$131.1 million in 2024, then skyrocketed by 110.86% to $14.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $14.2 million in Q4 2025, -$178.0 million in Q3 2025, and $101.1 million in Q2 2025.